Trial Profile
A Proof of Concept Study to Determine the Minimum Effective Dose and to Assess the Efficacy and Safety of Subcutaneous Injections of FPFS-1169 in Parkinson's Disease Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Aug 2019
Price :
$35
*
At a glance
- Drugs FPFS 1169 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Fujimoto Pharmaceutical
- 02 Aug 2019 Status changed from recruiting to completed.
- 18 Jul 2014 New trial record